rabbit anti-Helicobacterpylori monoclonal antibody (Poly) 6206

rabbit anti-Helicobacterpylori monoclonal antibody Poly 6206

antibody
Tested applications IHC
Recommended dilutions Concentrated 1:100-200
Application Notes Positive control: H. pylori infected tissue
Immunogen Total lysate of Helicobacter pylori
Size and concentration 7 mL prediluted or 0.1, 0.5, 1.0 mL and concentrated
Form liquid
Storage Instructions 2-8°C for short term, for longer term at -20°C. Avoid freeze / thaw cycles.
Purity affinity purified
Clonality monoclonal
Isotype IgG
Compatible secondaries goat anti-rabbit IgG, H&L chain specific, peroxidase conjugated, conjugated polyclonal antibody 9512 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody 2079 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody 7863 goat anti-rabbit IgG, H&L chain specific, Cross Absorbed polyclonal antibody 2371 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1715 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1720
Isotype control Rabbit polyclonal - Isotype Control

target relevance
Structure Helicobacter pylori, previously known as Campylobacter pylori, is a gram-negative, flagellated, helical bacterium. Mutants can have a rod or curved rod shape, and these are less effective. Its helical body (from which the genus name, Helicobacter, derives) is thought to have evolved in order to penetrate the mucous lining of the stomach, helped by its flagella, and thereby establish infection. The bacterium was first identified as the causal agent of gastric ulcers in 1983 by the Australian doctors Barry Marshall and Robin Warren.
Biotechnology In the diagnosis of H. pylori infections, a distinction is made between non-invasive and invasive methods. Invasive procedures contain histology, urease rapid test and microbiological techniques such as cultivation and PCR. The C13-breath test, the Helicobacter pylori antigen detection in stool samples and serological antibody detection based on ELISA or immunoblot belong to the group of non-invasive methods. The detection of serum antibodies can be used for therapy control after eradication therapy
Involvement in disease More than 50% of the world's population harbor Helicobacter pylori in their upper gastrointestinal tract. As a consequence, infections with this spirally formed, gram-negative bacterium belong to the most frequently occuring chronic bacterial diseases. 80 to 90% of all gastritis cases are traceable to an Helicobacter pylori infection. The person-to-person transmission is still not fully elucidated, but oral-oral and faecal-oral route mechanisms are discussed. Diseases associated with H. pylori infections include Ulcus duodeni, Ulcus ventriculi, stomach cancer and the seldom occuring MALT (Mucosa Associated Lymphatic Tissue) lymphoma. Phenotypic differences between different Helicobacter pylori isolates are limited to their ability to express the vacuolating cytotoxin (VacA) and its associated gene products (cytotoxin-associated genes; CagA). Due to phenotypic differences Helicobacter pylori isolates can be divided into virulent (type I) and non-virulent (type II) strains. Patients suffering from peptic or duodenal ulcers are more frequently infected with VacA and CagA producing Helicobacter pylori type I strains. Diagnose I